Evidence map›Paper›PMID 35291303›Full record

ArticleResearch square2022

Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19.

Shohei Eto, Yoko Nukui, Miyuki Tsumura, Yu Nakagama, Kenichi Kashimada, Yoko Mizoguchi, Takanori Utsumi, Maki Taniguchi, Fumiaki Sakura, Kosuke Noma and 19 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 9 institutions in 3 countries.

Shohei EtoHiroshima University Graduate School of Biomedical and Health Science.
Yoko NukuiKyoto Prefectural University of Medicine.
Miyuki TsumuraHiroshima University Graduate School of Biomedical and Health Science.
Yu NakagamaOsaka City University.
Kenichi KashimadaTokyo Medical and Dental University.
Yoko MizoguchiHiroshima University Graduate School of Biomedical and Health Science.
Takanori UtsumiHiroshima University Graduate School of Biomedical and Health Science.
Maki TaniguchiHiroshima University Graduate School of Biomedical and Health Science.
Fumiaki SakuraHiroshima University Graduate School of Biomedical and Health Science.
Kosuke NomaHiroshima University Graduate School of Biomedical and Health Science.
Yusuke YoshidaHiroshima University Hospital.
Shinichiro OhshimoHiroshima University Graduate School of Biomedical and Health Science.
Shintaro NagashimaHiroshima University Graduate School of Biomedical and Health Sciences.
Keisuke OkamotoTokyo Medical and Dental University.
Akifumi EndoTokyo Medical and Dental University Hospital.
Kohsuke ImaiTokyo Medical and Dental University.
Hirokazu KaneganeTokyo Medical and Dental University.
Hidenori OhnishiGifu University Graduate School of Medicine.
Shintaro HirataHiroshima University Hospital.
Eiji SugiyamaEmeritus Professor of Hiroshima University.
Nobuaki ShimeHiroshima University Graduate School of Biomedical and Health Science.
Masanori ItoHiroshima University Hospital.
Hiroki OhgeHiroshima University Hospital.
Yasutoshi KidoOsaka City University.
Paul BastardUniversity of Paris.
Jean-Laurent CasanovaRockefeller Branch, The Rockefeller University.
Junko TanakaHiroshima University Graduate School of Biomedical and Health Sciences.
Tomohiro MorioTokyo Medical and Dental University.
Satoshi OkadaHiroshima University Graduate School of Biomedical and Health Sciences.ORCID 0000-0002-4622-5657
Hiroshima University · JPTokyo Medical and Dental University · JPHiroshima University Hospital · JPOsaka City University · JPGifu University · JPKyoto Prefectural University of Medicine · JPRockefeller University · USTokyo Medical and Dental University Hospital · JPUniversité Paris Cité · FR

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Monogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19R01AI088364 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova, Shen-Ying Zhang · 2010 to 2026
$8.7M
Inborn errors of immunity in patients with life-threatening COVID-19R01AI163029 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT, ZHANG, QIAN · 2021 to 2025
$3.7M
NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI088364NIAID NIH HHS R01 AI163029
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35291303
PMCPMC8923117
OpenAlexW4221000413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.